EZASSI SIGNALS

Contract Manufacturing Consolidation and Capacity (North America)

Commercial Signals · September 2026

A Commercial watch on who is buying, building, closing or pulling in-house the contract manufacturing capacity that small brands depend on, across supplements, food and personal care. It is written for a contract manufacturer asking who is about to take its customers, who might buy it, and where capacity is opening or closing. Six signals from one cycle.

#	SIGNAL	CONFIDENCE	HORIZON	STATUS
1	Robinson Pharma's back-to-back 2026 expansions widen the scale gap against smaller supplement CMOs	Medium	Immediate (0–3 months)	Review
2	Foreign and brand strategic buyers are acquiring US supplement contract manufacturing plants, opening a new competitive and exit dynamic for independent CMOs	Medium	Short-term (3–12 months)	Review
3	Liquid supplement manufacturing is attracting simultaneous platform investment from three separate operators, signaling format-level consolidation pressure on independent liquid CMOs	Medium	Short-term (3–12 months)	Review
4	A billion-dollar Nestlé VMS divestiture to Yellow Wood Partners and Truvant's acquisition of Multi-Pak together signal PE accumulation of supplement manufacturing and packaging infrastructure	Medium	Short-term (3–12 months)	Verified
5	Published MOQ and lead-time data reveal a structural format barrier: gummies and softgels require materially longer timelines and larger minimum runs than capsules and powders, reinforcing large-CMO advantages in those formats	Medium	Immediate (0–3 months)	Review
6	A WARN filing for a food co-manufacturer and a brand plant consolidation within two days of each other in September 2026 signal capacity releasing in food production, though the displaced customer fate is unknown	Medium	Immediate (0–3 months)	Verified

Every signal rests on two or more dated events. Confidence is published as a band. Where a signal sits below High, the reasoning names the evidence that is missing. Status says where the evidence stands: Verified, Review, or Inconclusive — we looked, and the evidence does not yet support a firmer call.

SIGNAL 1 OF 6

Robinson Pharma's back-to-back 2026 expansions widen the scale gap against smaller supplement CMOs

MEDIUM **Immediate (0–3 months)** · Infrastructure & Supply Chain Signals · **Review**

Two separate Robinson Pharma capacity additions in 2026 — a January line-level build-out and an August facility opening — together signal an accelerating scale divergence that pressures 20-to-250-person contract manufacturers competing in softgels, capsules, tablets, powders, and liquids.

REASONING

This watch tracks new plants or expansions over 100,000 square feet and asks what each move does to a small CMO's competitive position. Two documented Robinson Pharma events in the same calendar year cross that threshold and together indicate a deliberate, multi-phase capacity program rather than a one-off investment. The January 2026 announcement added a high-speed liquid line and increased tablet compression machines from eight to eleven and capsule lines from nine to thirteen. The August 3, 2026 Irvine facility opening is described as Robinson's tenth US warehouse location and a major expansion covering softgels, capsules, tablets, powders, and liquid formulations. A September 2026 report characterizes the Irvine move as a 75 million dollar facility purchase and the broader program as a 115 million dollar infrastructure investment. No single event here is the signal; the pattern of sequential build-out across multiple dosage forms within one year is. The square footage figure could not be confirmed and is not used as a stated fact; the facility's status as a major, multi-format expansion is supported by and independently.

PATTERN

Robinson Pharma expanded tablet, capsule, softgel, and liquid capacity in January 2026 by adding lines and machines. It then opened a new Irvine, California facility on August 3, 2026, described as its tenth US location and covering softgels, capsules, tablets, powders, and liquids. A September 2026 report described the Irvine move as a 75 million dollar facility purchase within a 115 million dollar infrastructure program. Both events concern the same operator and overlapping dosage forms within a single year.

IMPLICATION

A small CMO serving the same dosage forms — softgels, capsules, tablets, powders, liquids — now competes against a ten-facility operator that added capacity twice in twelve months and committed over 100 million dollars in reported infrastructure spending. Customers shopping on price or scale will have an increasingly credible large-CMO alternative, tightening the customer-retention window for operators that cannot match throughput or certification breadth. Exit multiples for small CMOs in these formats may compress if acquirers can instead contract with or build alongside Robinson.

RECOMMENDED ACTION

Map your current customer roster against the dosage forms Robinson Pharma added capacity in; for each overlap, assess whether your minimum order quantities and lead times remain competitive, and accelerate any pending certification (NSF, SQF, USP) that Robinson already holds to reduce customer defection risk.

SOURCES & WHAT THEY SIGNAL

- **Robinson Pharma Opens 10th US Facility as Contract Manufacturing Demand Grows — Nutritional Outlook** — Confirms the August 2026 Irvine facility opening as Robinson's tenth US location and frames it as a response to growing demand, establishing the strategic intent behind the expansion.
- **Robinson Pharma Announces Major Expansion with New Facility in Irvine, California — PR Newswire** — Primary announcement of the August 3, 2026 Irvine facility, naming dosage forms and certifications; the trigger event for the expansion signal.
- **Robinson Pharma Expands Manufacturing Capacity With New High-Speed Liquid Line — robinsonpharma.com** — Documents the January 2026 line-level expansion — liquid, tablet, capsule, softgel — establishing that the Irvine opening was the second, not first, major capacity move of the year.
- **Robinson Pharma Receives Above and Beyond Supplier Award from Bausch and Lomb — NBC Right Now** — Provides the 75 million dollar facility purchase figure and the 115 million dollar total infrastructure investment characterization, contextualizing the scale of Robinson's 2026 capital commitment.

SIGNAL 2 OF 6

Foreign and brand strategic buyers are acquiring US supplement contract manufacturing plants, opening a new competitive and exit dynamic for independent CMOs

MEDIUM **Short-term (3–12 months)** · Commercial & Market Signals · **Review**

Three transactions in the first half of 2026 — TopGum's acquisition of PL Developments' US gummy operations, Applied Nutrition's acquisition of Nutrablend, and Ananda Health's acquisition of Elixinol's US operations — show that foreign brands and vertically integrating domestic players are buying finished-goods manufacturing capacity rather than contracting it out, compressing the independent CMO customer base while simultaneously creating exit paths.

REASONING

This watch tracks foreign strategic buyers entering the US through a plant purchase and brands acquiring plants. Three events across different buyer nationalities and dosage forms within the same reporting year constitute a pattern, not isolated incidents. TopGum is an Israeli company acquiring its first US production platform in gummies and chewable supplements for up to 35 million dollars. Applied Nutrition is a UK sports-nutrition brand acquiring a US manufacturer including a 107,000-square-foot Buffalo, New York facility for 16 million dollars. Ananda Health is a US vertically integrated supplement manufacturer that acquired Elixinol's US operations and explicitly announced expansion of contract manufacturing and third-party logistics for brand partners. While TopGum and Applied Nutrition fall just outside the August–September 2026 window, the watch covers the category for foreign buyers and brand insourcing; all three events fall within 2026 and together establish a directional pattern. Confidence is held at Medium because the TopGum and Applied Nutrition transactions are pre-August and the Ananda deal lacks a disclosed PE sponsor or valuation, limiting the ability to assess pricing or financing conditions.

PATTERN

TopGum (Israel) agreed to acquire PL Developments' US gummy manufacturing operations for up to 35 million dollars, giving it its first US production platform in gummies and chewable supplements (May 2026). Applied Nutrition (UK) acquired Nutrablend, a US manufacturer, for 16 million dollars including a 107,000-square-foot Buffalo, New York facility (Q2 2026). Ananda Health acquired Elixinol's US operations and announced expansion of contract manufacturing services across tinctures, topicals, molten and hot-fill products, and gummies, with powders and capsules expected to be added.

IMPLICATION

For an independent US supplement CMO, these transactions carry two opposite implications simultaneously. On the downside, each acquired plant removes a potential contract-manufacturing customer and adds a vertically integrated competitor that may bid aggressively on third-party work to fill its newly owned capacity. On the upside, the willingness of foreign and brand buyers to pay for US-based manufacturing plants establishes a demonstrated acquisition pathway — a small CMO with a differentiated dosage form, clean regulatory record, and a defensible customer list is a plausible target for the next buyer in this category. Exit planning should account for both effects.

RECOMMENDED ACTION

Prepare a brief asset profile — dosage forms, certifications, customer tenure, utilization, and facility ownership structure — that would be immediately legible to a foreign or brand strategic buyer; use the disclosed transaction values (35 million dollars for a gummy platform, 16 million dollars for a 107,000-square-foot multi-format facility) as rough comparables when discussing valuation expectations with an M&A adviser.

SOURCES & WHAT THEY SIGNAL

- **Ananda Health Acquires Elixinol's US Operations — National Law Review** — Confirms the acquisition and the stated intent to expand contract manufacturing services, showing a US vertically integrated player using an acquisition to enter third-party CMO competition.
- **TopGum Expands US Manufacturing Footprint With Acquisition of PL Developments — Nutritional Outlook** — Documents TopGum's entry into US gummy and chewable supplement manufacturing through an acquisition valued at up to 35 million dollars, establishing the foreign-buyer pattern.
- **TopGum expands US footprint with $35m PL** — Confirms TopGum's acquisition of PL Developments' US gummy manufacturing operations for up to $35 million as its first US production platform.
- **Supplement Industry Deals of Q2 2026 — NutraIngredients** — Documents Applied Nutrition's acquisition of Nutrablend for 16 million dollars including the Buffalo, New York facility, establishing a second foreign-brand acquisition of US supplement manufacturing capacity in 2026.
- **TopGum Signs Letter of Intent to Acquire US Manufacturing Operations — Pharma Exec** — Corroborates the TopGum acquisition of US gummy manufacturing capacity and provides additional context on the transaction structure.

SIGNAL 3 OF 6

Liquid supplement manufacturing is attracting simultaneous platform investment from three separate operators, signaling format-level consolidation pressure on independent liquid CMOs

MEDIUM **Short-term (3–12 months)** · Infrastructure & Supply Chain Signals · **Review**

Three distinct operators — Riverside-backed WB Blends, Ananda Health, and Robinson Pharma — each moved to add or expand liquid supplement production capability in 2026, suggesting that liquid formats are becoming a battleground where independent liquid CMOs will face newly capitalized competitors with adjacent format scale.

REASONING

This watch looks for patterns in dosage-form-specific capacity additions. Liquid formats — tinctures, extracts, herbal liquids, liquid shots — appear across three separate operator moves within the same year. WB Blends, a division of Riverside Company-backed Western Botanicals, partnered with Yellow Emperor specifically to add tincture, extract, and herbal liquid formulation capabilities to its existing capsule and powder platform. Ananda Health's acquisition of Elixinol's US operations includes tinctures, topicals, and molten and hot-fill products, with the announcement explicitly describing contract manufacturing expansion in these formats. Robinson Pharma's January 2026 expansion added a high-speed liquid production line, and the August Irvine facility covers liquid formulations. No single event establishes a liquid shortage or demand surge — these are supply-side moves. But three operators independently targeting the same format within twelve months is a directional signal about where capitalized platforms see under-consolidated opportunity. Confidence is held at Medium because the WB Blends event has no disclosed date and the Robinson liquid additions are part of a multi-format program, so the liquid-specific demand driver cannot be isolated from the available evidence.

PATTERN

Riverside Company-backed WB Blends announced a strategic partnership with Yellow Emperor, a liquid dietary supplement manufacturer in Eugene, Oregon, to add tincture, extract, and herbal liquid formulation capabilities to its capsule and powder platform. Ananda Health acquired Elixinol's US operations, gaining tincture, topical, molten, and hot-fill manufacturing and announcing contract manufacturing expansion in those formats. Robinson Pharma added a high-speed liquid production line in January 2026 and opened its Irvine, California facility in August 2026 covering liquid formulations among other dosage forms.

IMPLICATION

An independent liquid supplement CMO — one specializing in tinctures, extracts, or liquid shots — now faces three better-capitalized competitors that each entered or expanded liquid formats within the past twelve months: one PE-backed platform, one vertically integrated acquirer, and one large full-service CMO. The competitive moat around liquid formats, which historically required specialized equipment and regulatory expertise, is narrowing. For small liquid CMOs, the near-term priority is locking customers into multi-year agreements before these platforms reach full utilization, and the medium-term priority is assessing whether the same consolidation trend makes them an attractive acquisition target.

RECOMMENDED ACTION

Identify the two or three customers that represent the majority of your liquid format revenue; approach each about a capacity-reservation or volume-commitment arrangement before the newly expanded competitors begin active customer solicitation.

SOURCES & WHAT THEY SIGNAL

- **Ananda Health Acquires Elixinol's US Operations — National Law Review** — Confirms that Ananda Health's acquisition includes tincture, topical, and hot-fill liquid manufacturing and that the company plans to expand contract manufacturing in those formats.
- **Robinson Pharma Opens 10th US Facility as Contract Manufacturing Demand Grows — Nutritional Outlook** — Confirms liquid formulations are among the dosage forms covered by Robinson Pharma's August 2026 Irvine facility, reinforcing the multi-operator liquid expansion pattern.
- **WB Blends and Yellow Emperor Expand Liquid Supplement Manufacturing — Nutraceutical Business Review** — Documents Riverside-backed WB Blends entering liquid supplement manufacturing through a partnership with Yellow Emperor, establishing PE-backed platform expansion into the liquid format.
- **Robinson Pharma Expands Manufacturing Capacity With New High-Speed Liquid Line — robinsonpharma.com** — Documents Robinson Pharma's January 2026 addition of a liquid production line, establishing it as a third operator expanding into liquid supplement formats within the same year.

SIGNAL 4 OF 6

A billion-dollar Nestlé VMS divestiture to Yellow Wood Partners and Truvant's acquisition of Multi-Pak together signal PE accumulation of supplement manufacturing and packaging infrastructure

MEDIUM **Short-term (3–12 months)** · Commercial & Market Signals · **Verified**

Two transactions announced in August and September 2026 — Truvant's acquisition of Multi-Pak Packaging and Yellow Wood Partners' agreement to acquire Nestlé's VMS manufacturing and private-label platform for one billion dollars — suggest that private equity is positioning to consolidate supplement production and packaging assets vacated or restructured by large brand owners.

REASONING

This watch looks for PE platform acquisitions and for brand divestitures that include manufacturing assets. The Truvant-Multi-Pak transaction on August 25, 2026 is a confirmed acquisition of a contract packager and co-manufacturer serving VMS, OTC, beauty, and personal care customers in New Jersey. The Nestlé-Yellow Wood transaction announced September 1, 2026 involves seven brands, a US private-label supplements business, and associated manufacturing, packaging, warehousing, and distribution operations for one billion dollars. Together they represent two separate PE-linked buyers acquiring supplement manufacturing and packaging infrastructure within five weeks of each other. Neither transaction is a classic CMO roll-up add-on — Truvant's sponsor and strategy are not disclosed in the available sources, and Yellow Wood is acquiring a brand portfolio alongside the manufacturing assets — so the roll-up interpretation is inferential rather than direct. Confidence is held at Medium for that reason and because the Nestlé deal will not close until the first half of 2027 at the earliest, limiting near-term competitive effects.

PATTERN

Truvant acquired Multi-Pak Packaging, a West Caldwell, New Jersey contract packager and co-manufacturer serving VMS, OTC, beauty and personal care, and medical device customers, announced August 25, 2026. Yellow Wood Partners agreed to acquire Nestlé's mainstream VMS business — including seven brands, a US private-label supplements business, and manufacturing, packaging, warehousing, and distribution operations — for one billion dollars, announced September 1, 2026, with closing expected in the first half of 2027.

IMPLICATION

If Yellow Wood activates the acquired private-label manufacturing and distribution infrastructure for third-party customers, it could become a mid-scale CMO competitor with Nestlé-inherited capacity — potentially underpricing independent CMOs that lack comparable volume. For small supplement CMOs, the more immediate concern is that Truvant's acquisition of Multi-Pak removes an independent co-packing option in the Northeast that previously served small and mid-sized brands, concentrating packaging choices. Both transactions reward early monitoring of Yellow Wood's post-close strategy, which will determine whether manufacturing assets are rationalized or expanded.

RECOMMENDED ACTION

Track Yellow Wood's post-close public statements for any indication that they will open the acquired Nestlé private-label manufacturing capacity to third-party customers; if they do, model the pricing pressure that a well-capitalized incumbent supplier entering the open CMO market would create for your customer segments.

SOURCES & WHAT THEY SIGNAL

- **Truvant Acquires New Jersey-Based Multi-Pak Packaging — PR Newswire** — Confirms the August 25, 2026 acquisition of a VMS and OTC contract packager and co-manufacturer, establishing Truvant as a buyer aggregating supplement and personal-care co-manufacturing capacity.
- **Nestlé to Sell Vitamins Business to Private Equity for One Billion Dollars — Bloomberg** — Documents Yellow Wood Partners' agreement to acquire Nestlé's VMS business including associated manufacturing and logistics operations for one billion dollars, establishing a major divestiture of supplement manufacturing infrastructure to a PE buyer.
- **Nestlé to Sell Mainstream Supplements Business — Yahoo Finance / Financial Times** — Corroborates the Bloomberg report on the Nestlé-Yellow Wood transaction, confirming the manufacturing, packaging, warehousing, and distribution assets are included in the sale.

SIGNAL 5 OF 6

Published MOQ and lead-time data reveal a structural format barrier: gummies and softgels require materially longer timelines and larger minimum runs than capsules and powders, reinforcing large-CMO advantages in those formats

MEDIUM **Immediate (0–3 months)** · Infrastructure & Supply Chain Signals · **Review**

Minimum order quantity and lead-time data published by supplement contract manufacturers in 2026 show that gummies and softgels carry higher production minimums and longer lead times than capsules and powders, creating format-specific structural barriers that favor larger CMOs and penalize small brands.

REASONING

This signal differs from the transaction-based ones: it rests on operating data published by manufacturers rather than on corporate events. NutraSeller states gummies require 12 to 14 weeks versus 6 to 8 weeks for capsules and powders, and lists a 2,500-unit minimum for capsules and an approximately 8,333-unit minimum for custom gummies. Atrium Scientific Group states gummy minimums of 10,000 to 50,000 units versus capsule minimums of 5,000 to 25,000 units on one page, and 20,000 to 50,000 units for gummies on another. Sun Nutrition publishes a 6 to 10 week lead time across formats including gummies, with a 5,000-unit minimum per SKU, though it does not break out gummies separately at a higher tier. These are marketing pages, not independent market reports, so they reflect each CMO's own terms — not a market-wide survey. Confidence is held at Medium because the pages establish that these CMOs set higher gummy and softgel requirements, not that the market uniformly does. However, the consistency across multiple separate operators is meaningful as a directional signal for customers trying to evaluate format viability.

PATTERN

NutraSeller publishes lead times of 12 to 14 weeks for gummies and softgels versus 6 to 8 weeks for capsules and powders, and lists a 2,500-unit minimum for capsules compared to approximately 8,333 units for custom gummies. Atrium Scientific Group states gummy minimums of 10,000 to 50,000 units compared to capsule minimums of 5,000 to 25,000 units, and separately states 20,000 to 50,000 units for gummies versus lower minimums for other formats. Sun Nutrition states a 5,000-unit minimum across formats and a 6 to 10 week lead time from formula approval to finished goods.

IMPLICATION

For a small CMO, this format structure has two implications. First, gummy and softgel production remains gatekept by capital-intensive minimums and longer cycle times, meaning small brands seeking small-batch gummy runs have limited options — creating a viable niche for any CMO willing to serve small-batch gummy customers at a premium. Second, the same structure means that any large CMO expanding gummy capacity can capture customers unable to meet the higher minimums that currently prevail at several major operators, potentially undercutting a small CMO's niche positioning.

RECOMMENDED ACTION

If you operate in gummies or softgels, review whether your stated minimums and lead times remain competitive with or below the benchmarks that multiple independent CMOs are publicly advertising;

consider publishing differentiated small-batch terms as a specific customer acquisition tool for brands that cannot meet large-CMO minimums.

SOURCES & WHAT THEY SIGNAL

- **Contract Supplement Manufacturing — NutraSeller** — States gummy and softgel lead times of 12 to 14 weeks versus 6 to 8 weeks for capsules and powders, and lists a capsule minimum of 2,500 units versus approximately 8,333 units for custom gummies, establishing format-differentiated operating terms at one CMO.
- **Contract Manufacturing — Sun Nutrition** — States a 5,000-unit minimum per SKU and 6 to 10 week lead time across formats, providing a second data point on market-level operating terms.
- **Minimum Order Quantity for Private Label Supplements — Atrium Scientific Group** — States gummy minimums of 10,000 to 50,000 units versus capsule minimums of 5,000 to 25,000 units at a third CMO, corroborating the gummy-versus-capsule barrier pattern.
- **Dietary Supplement Contract Manufacturer USA Guide — Atrium Scientific Group** — States 20,000 to 50,000-unit minimums for gummies alongside lower minimums for other formats, reinforcing the format-differentiated minimum structure across a broader set of comparisons.

SIGNAL 6 OF 6

A WARN filing for a food co-manufacturer and a brand plant consolidation within two days of each other in September 2026 signal capacity releasing in food production, though the displaced customer fate is unknown

MEDIUM **Immediate (0–3 months)** · Commercial & Market Signals · **Verified**

No Meat Factory's WARN filing for its Stanwood, Washington co-manufacturing plant and Amy's Kitchen's WARN filing for its Santa Rosa, California production facility, both in September 2026, represent a concentrated release of food production capacity within a two-day window, with downstream effects on displaced customers and idled assets yet to be determined.

REASONING

This watch tracks plant closures and WARN notices and asks specifically what happens to displaced customer contracts and idled assets. No Meat Factory is described as a co-manufacturer, and its Stanwood, Washington WARN notice for approximately 123 employees with a September 16, 2026 cessation date is the most directly in-scope of the two events. Amy's Kitchen's Santa Rosa WARN notice dated September 17, 2026 affecting 200 employees is a brand-owned plant consolidation rather than a contract manufacturing closure, with production reportedly moving to Medford, Oregon and Pocatello, Idaho. This watch excludes ordinary brand plant closures unless they involve a relevant outsourcing or insourcing move; Amy's production relocation to owned facilities is likely in-scope as an insourcing consolidation, though the available source does not confirm whether Amy's uses any external co-manufacturers at the closing site. Confidence is held at Medium because: the No Meat Factory LinkedIn source is not a primary filing; the Amy's classification as a contract manufacturing event is uncertain; and the current findings contain no evidence on what happened to displaced customers, idled equipment, or plant ownership after either filing.

PATTERN

No Meat Factory, a Canadian alternative-protein co-manufacturer, filed or announced a WARN notice for its Stanwood, Washington facility affecting approximately 123 employees, with operations scheduled to cease September 16, 2026. Amy's Kitchen filed a California WARN notice dated September 17, 2026 for its Santa Rosa facility at 2330 Northpoint Parkway, affecting 200 employees, with a trade source indicating production was moving to Medford, Oregon and Pocatello, Idaho.

IMPLICATION

The No Meat Factory closure removes a US co-manufacturing option for alternative-protein brands that relied on that Stanwood plant. Any brand that co-manufactured there must now find an alternative, and the idled facility represents a potential acquisition or lease opportunity for a food CMO seeking West Coast alternative-protein capacity. The Amy's consolidation is a reminder that brand-owned plant rationalization also reshapes the customer pool — brands that lose access to internal overflow capacity may enter the external co-manufacturing market, increasing demand for food CMO services. Both outcomes are speculative from the current evidence, which establishes only that the closures occurred, not where the production or customers went.

RECOMMENDED ACTION

Pull the full Washington State WARN database entry for No Meat Factory to confirm the employer, address, affected-worker count, and layoff type; then contact the facility's landlord or county assessor to determine ownership status and whether the building or equipment is available for lease or acquisition by a food co-manufacturer seeking West Coast capacity.

SOURCES & WHAT THEY SIGNAL

- **Alt-Meat Co-Packer No Meat Factory to Exit US Market — Food and Beverage Business Magazine via LinkedIn** — Reports No Meat Factory's closure of its Stanwood, Washington co-manufacturing facility affecting approximately 123 employees, establishing the primary WARN signal for a food co-manufacturer exit.
- **Washington State WARN Layoff and Closure Database — Employment Security Department** — Identifies the primary state record source for verifying the No Meat Factory WARN filing, employer details, and affected-worker count.
- **Latest News in the Food and Beverage Industry — Powder Bulk Solids** — Trade source indicating Amy's Kitchen planned to move Santa Rosa production to Medford, Oregon and Pocatello, Idaho, contextualizing the WARN as a consolidation rather than an exit from manufacturing.
- **California WARN Report — California Employment Development Department** — The California WARN data file containing the Amy's Kitchen Santa Rosa notice dated September 17, 2026, affecting 200 employees at 2330 Northpoint Parkway.

PUT A WATCH ON YOUR QUESTION

A watch on your question runs every cycle.

These signals came from one cycle of a standing watch. Name a company, a market or a regulation, and the watch keeps running whether or not anyone opens the platform. Every signal arrives rated for confidence and horizon, with the dated events behind it and the sources that carry the weight.

See all the samples and tell us your question at ezassi.com/ezassi-signals-sample-library.

info@ezassi.com · ezassi.com